Telbivudine preserves T-helper 1 cytokine production and downregulates programmed death ligand 1 in a mouse model of viral hepatitis

Journal of Viral Hepatitis

Volumn 17, Issue SUPPL. 1, 2010, Pages 24-33

  Wu, Z G ^a   Yan, W M ^a   Guo, W ^a   Chen, T ^a   Zou, Y ^a   Wang, H W ^a   Wang, X J ^a   Yang, X J ^a   Lu, Y L ^a   Luo, X P ^b   Ning, Q ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Hepatitis B virus; Interleukin; Oral nucleos(t)ide analogue; Programmed death ligand 1; Tumour necrosis factor

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 4; LAMIVUDINE; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN; TELBIVUDINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DOWN REGULATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; FEMALE; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNE RESPONSE; IMMUNE SYSTEM; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MACROPHAGE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TH1 CELL; VIRUS HEPATITIS; VIRUS REPLICATION;

ANIMALS; ANTIGENS, CD274; ANTIVIRAL AGENTS; CELLS, CULTURED; CYTOKINES; FEMALE; HEPATITIS, VIRAL, ANIMAL; IMMUNOLOGIC FACTORS; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MURINE HEPATITIS VIRUS; NUCLEOSIDES; PYRIMIDINONES; SURVIVAL ANALYSIS; TH1 CELLS;

EID: 77749315681     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01268.x     Document Type: Article

References (43)

1. World Health Organization. Hepatitis B Fact Sheet. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/ (accessed 31 January 2009).
2. Ferrari C, Penna A, Bertoletti A et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990 145 : 3442 3449.
3. Rehermann B, Fowler P, Sidney J et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995 181 : 1047 1058.
4. Thimme R, Wieland S, Steiger C et al. CD8 (+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003 77 : 68 76.
5. Penna A, Artini M, Cavalli A et al. Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 1996 98 : 1185 1194.
6. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009 50 : 227 242.
7. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007 45 : 507 539.
8. Tilg H. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 1997 112 : 1017 1021.
9. Ning Q, Brown D, Parodo J et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998 160 : 3487 3493.
10. Ning Q, Lakatoo S, Liu M et al. Induction of prothrombinase fgl2 by the nucleocapsid protein of virulent mouse hepatitis virus is dependent on host hepatic nuclear factor-4 alpha. J Biol Chem 2003 278 : 15541 15549.
11. Liu WL, Su WC, Cheng CW et al. Ribavirin up-regulates the activity of double-stranded RNA-activated protein kinase and enhances the action of interferon-alpha against hepatitis C virus. J Infect Dis 2007 196 : 425 434.
12. Bryant ML, Bridges EG, Placidi L et al. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother 2001 45 : 229 235. (Pubitemid 32039120)
13. Golitsina N, Danehy F, Fellows R. Telbivudine phosphorylation by three enzymes: implications for antihepatitis B virus activity in vitro and in the clinic. Hepatology 2006 44 : 561A.
14. Hernandez-Santiago B, Placidi L, Cretton-Scott E et al. Pharmacology of beta-L-thymidine and beta-L-2′-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus. Antimicrob Agents Chemother 2002 46 : 1728 1733.
15. Seifer M, Patty A, Dukhan D. Telbivudine (LDT) preferentially inhibits second (+) strand HBV DNA synthesis. J Hepatol 2005 42 : 151.
16. Lai CL, Gane E, Liaw YF et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007 357 : 2576 2588.
17. Liaw YF, Gane E, Leung N et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009 136 : 389 392.
18. Qin XM, Zhang JG, Su K, Yang C, Yan WM, Ning Q. Establishment and characterization of a chronic viral hepatitis model induced by murine hepatitis virus type 3. Virol Sin 2006 21 : 417 420.
19. Zhang J, Qin X, Wang XJ et al. A primary study of the subgroups of T lymphocytes in MHV-3 induced chronic viral hepatitis. Virol Sin 2007 22 : 339 346.
20. Levy GA, Adamson G, Phillips MJ et al. Targeted delivery of ribavirin improves outcome of murine viral fulminant hepatitis via enhanced anti-viral activity. Hepatology 2006 43 : 581 591.
21. Hu P, Jiang J, Wang H et al. Single-dose and multiple-dose pharmacokinetics and safety of telbivudine after oral administration in healthy Chinese subjects. J Clin Pharmacol 2006 46 : 999 1007.
22. Zhou XJ, Lim SG, Lloyd DM, Chao GC, Brown NA, Lai CL. Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications. Antimicrob Agents Chemother 2006 50 : 874 879.
23. Shigemi S, Tsutsumi H, Takeuchi R, Matsuda K, Imai S, Ogra PL. Enhanced cytokine production by milk macrophages following infection with respiratory syncytial virus. J Leukoc Biol 1997 61 : 630 636.
24. Boni C, Penna A, Bertoletti A et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 2003 39 : 595 605.
25. + T-cell reactivity. Antimicrob Agents Chemother 2008 52 : 312 320.
26. Evans A, Riva A, Cooksley H et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion. Hepatology 2008 48 : 759 769.
27. Ding JW, Ning Q, Liu MF et al. Fulminant hepatic failure in murine hepatitis virus strain 3 infection: tissue-specific expression of a novel fgl2 prothrombinase. J Virol 1997 71 : 9223 9230.
28. Ding JW, Ning Q, Liu MF et al. Expression of the fgl2 and its protein product (prothrombinase) in tissues during murine hepatitis virus strain-3 (MHV-3) infection. Adv Exp Med Biol 1998 440 : 609 618.
29. Levy GA, Liu M, Ding J et al. Molecular and functional analysis of the human prothrombinase gene (HFGL2) and its role in viral hepatitis. Am J Pathol 2000 156 : 1217 1225.
30. Marsden PA, Ning Q, Fung LS et al. The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis. J Clin Invest 2003 112 : 58 66.
31. Zhu C, Sun Y, Luo X, Yan W, Xi D, Ning Q. Novel mfgl2 antisense plasmid inhibits murine fgl2 expression and ameliorates murine hepatitis virus type 3-induced fulminant hepatitis in BALB/cJ mice. Hum Gene Ther 2006 17 : 589 600.
32. Mosmann TR, Coffman RL. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989 7 : 145 173.
33. Levy GA, Shaw R, Leibowitz JL, Cole E. The immune response to mouse hepatitis virus: genetic variation in antibody response and disease. Adv Exp Med Biol 1984 173 : 345 364.
34. Pope M, Chung SW, Mosmann T, Leibowitz JL, Gorczynski RM, Levy GA. Resistance of naive mice to murine hepatitis virus strain 3 (MHV-3) requires development of Th1, but not Th2 response, whereas pre-existing antibody protects against primary infection. J Immunol 1996 156 : 3342 3349.
35. Kägi D, Vignaux F, Ledermann B et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994 265 : 528 530.
36. Braun MY, Lowin B, French L, Acha-Orbea H, Tschopp J. Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus host disease. J Exp Med 1996 183 : 657 661.
37. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002 20 : 323 370.
38. Chisari FV. Hepatitis B virus transgenic mice: insights into the virus and the disease. Hepatology 1995 22 : 1316 1325.
39. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001 19 : 65 91.
40. Suri D, Schilling R, Lopes AR et al. Non-cytolytic inhibition of hepatitis B virus replication in human hepatocytes. J Hepatol 2001 35 : 790 797.
41. Agata Y, Kawasaki A, Nishimura H et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996 8 : 765 772.
42. Nishimura H, Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol 2001 22 : 265 268.
43. Barber DL, Wherry EJ, Masopust D et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006 439 : 682 687.